SCHEMBL4871634

SCHEMBL4871634

COc1cccc(C2(C(=O)NS(N)(=O)=O)CCN(C(c3ccccc3)c3ccccc3)CC2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 8/20 0.60
OPRD1 P41143 8/20 0.60
OPRK1 P41145 8/20 0.60
OPRL1 P41146 8/20 0.60
MAPT P10636 3/20 0.48
CYP3A4 P08684 3/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C9 P11712 2/20 0.46
KMT2A Q03164 1/20 0.45
USP2 O75604 3/20 0.44
LMNA P02545 3/20 0.43
ALDH1A1 P00352 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CYP1A2 P05177 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GAA P10253 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CACNA2D1 P54289 1/20 0.41
CACNA1B Q00975 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4878651 0.87 OPRM1 (0.56) OPRM1OPRD1OPRK1OPRL1MAPT
SCHEMBL5476317 0.84 OPRM1 (0.69) OPRM1OPRD1OPRK1OPRL1MAPT
SCHEMBL4880912 0.84 OPRM1 (0.69) OPRM1OPRD1OPRK1OPRL1MAPT
SCHEMBL4877793 0.84 OPRM1 (0.72) OPRM1OPRD1OPRK1OPRL1MAPT
SCHEMBL4868393 0.80 ALDH1A1 (0.48) OPRD1MAPTCYP3A4CYP2D6KMT2A
SCHEMBL4876648 0.79 ALDH1A1 (0.47) OPRD1MAPTCYP3A4CYP2D6KMT2A
SCHEMBL4876628 0.79 ALDH1A1 (0.47) OPRD1MAPTCYP3A4CYP2D6KMT2A
SCHEMBL4880538 0.76 SOAT1 (0.50) MAPTCYP3A4KMT2AUSP2ALDH1A1
SCHEMBL4883883 0.74 MMP1 (0.52) LMNAALDH1A1L3MBTL1
SCHEMBL434266 0.74 MAPT (0.53) OPRM1OPRD1OPRK1OPRL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096922-A1 Novel Sulfonamide derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-04-24 US disclosed
EP-1736467-A1 NOVEL SULFONAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096922-A1 Novel Sulfonamide derivative NR4A1, NR4A2, NR4A3 OPRM1 1290/4885OPRD1 628/4885OPRK1 2515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.